Teva Pharmaceutical Industries Limited (TEVA) Q2 FY26 Earnings Call

Teva raised its full-year revenue guidance midpoint by $75 million after innovative product revenue grew 43% year-over-year.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Length69 minutes
EPS$0.00
EPS consensus$0.05

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25

All TEVA earnings ยท Back to TEVA overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.